RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More informationThe European Medicines Agency (EMA) Management Board convened on 2nd October 2025, reviewing mid-year performance and endorsing strategic initiatives.
The European Medicines Agency (EMA) has released a draft reflection paper inviting public consultation on integrating patient experience data into the regulatory process.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) convened from 29th September to 2nd October 2025, addressing various aspects of medicine safety.
The FDA has finalised guidance on employing alternative tools to evaluate drug manufacturing facilities in pending applications.
The MHRA invites medical students and foundation doctors to explore how genetics can enhance prescribing safety and patient outcomes in the UK.
The MHRA has released updated guidance for conducting clinical trials that include in vitro diagnostic (IVD) devices.
The MHRA has released updated guidance for clinical trials that necessitate expert advice from specialist groups or committees.
The MHRA has released an updated version of its guidance on safety event management in clinical trials.
The MHRA has released updated guidance on the process for ending clinical trials, effective from 28th April 2026.
The MHRA has updated its guidance on modifying clinical trial approvals, introducing Route A and B processes to streamline amendments.